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Gene therapy restores vision in rd1 mice after
removal of a confounding mutation in Gpr179
Koji M. Nishiguchi1,*, Livia S. Carvalho1,*, Matteo Rizzi1, Kate Powell1, Sophia-Martha kleine Holthaus1,
Selina A. Azam1, Yanai Duran1, Joana Ribeiro1, Ulrich F.O. Luhmann1, James W.B. Bainbridge1,
Alexander J. Smith1 & Robin R. Ali1
The rd1 mouse with a mutation in the Pde6b gene was the ﬁrst strain of mice identiﬁed with a
retinal degeneration. However, AAV-mediated gene supplementation of rd1 mice only results
in structural preservation of photoreceptors, and restoration of the photoreceptor-mediated
a-wave, but not in restoration of the bipolar cell-mediated b-wave. Here we show that a
mutation in Gpr179 prevents the full restoration of vision in rd1 mice. Backcrossing rd1 with
C57BL6 mice reveals the complete lack of b-wave in a subset of mice, consistent with an
autosomal recessive Mendelian inheritance pattern. We identify a mutation in the Gpr179
gene, which encodes for a G-protein coupled receptor localized to the dendrites of
ON-bipolar cells. Gene replacement in rd1 mice that are devoid of the mutation in Gpr179
successfully restores the function of both photoreceptors and bipolar cells, which is main-
tained for up to 13 months. Our discovery may explain the failure of previous gene therapy
attempts in rd1 mice, and we propose that Grp179 mutation status should be taken into
account in future studies involving rd1 mice.
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he rd1 mouse, which was ﬁrst described in 1924, is
considered the ﬁrst mouse model of retinal degeneration
and was initially referred to as the rodless mouse1.I t
carries a naturally occurring nonsense mutation in the
photoreceptor cGMP phosphodiesterase 6b (Pde6b) gene and is
the oldest and most widely used animal model for studying the
mechanisms of retinal degeneration. The defective gene encodes
the b-subunit of rod PDE (bPDE), an essential component of the
phototransduction cascade, a molecular signalling pathway that
converts light stimulus into an electric signal in the outer
segments of rod photoreceptors2,3. The rod photoreceptor
degenerates rapidly in this model such that by 4 weeks of age,
the outer nuclear layer is left with a single layer of photoreceptors
consisting of cone photoreceptors4 that are subsequently lost
through a secondary unknown mechanism. It is thus one of the
most severe models of retinal degeneration identiﬁed to date.
Because rd1 mice have been readily available for many decades,
numerous attempts have been made to rescue visual function and
prevent degeneration in this model. Many attempts have been
made through either local or systemic intervention to rescue
directly the primary defect in the rod photoreceptors5–9 and/or
slow the secondary degeneration of the cones10–12. However,
providing effective and lasting phenotypic rescue has proven
elusive, the only achievement to date being partial histological
preservation with minimal, if any, functional rescue6,7,13,14. This
has led to the development of a wide-spread notion that the speed
of retinal degeneration in this model is too fast to allow a window
of opportunity for treatment14–19 This hypothesis has been
bolstered by an effective gene supplementation therapy in the
canine model of PDE6B deﬁciency (rcd1 dog)20 and in the
hypomorphic Pde6b-mutant (rd10) mouse15,18,19.A s
photoreceptor loss in these animals is slower, they provide a
greater window of opportunity for treatment than the rd1 mice.
These results suggested that the retinal degeneration caused by a
defective Pde6b gene is in principle amenable to structural and
function rescue by gene therapy, but the rate of photoreceptor
degeneration in the rd1 mice is too fast to allow for effective
rescue.
Recently, we have provided evidence to challenge the prevailing
consensus that the speed of photoreceptor degeneration in rd1
mice precludes effective rescue by demonstrating effective adeno-
associated virus (AAV)-mediated gene supplementation therapy
in Aipl- deﬁcient mice21,22. Knockout of the Aipl1 gene results in
post-transcriptional reduction of all the three subunits of the
cGMP-PDE holoenzyme (a,  and g); in this model the retinal
degeneration is even faster than in the rd1, resulting in a complete
loss of photoreceptors by 3 weeks of age, indicating that the
treatment window should be even smaller in the Aipl1 / 
mouse compared with rd1 mice16,23.
Since the ﬁrst attempts to rescue the rd1 mouse, there have
been considerable advances in retinal gene therapy, including the
availability of new AAV serotypes that allow highly efﬁcient and
rapid photoreceptor transduction. Following our successful
treatment of Aipl1 /  mice we wanted to determine whether
an optimized gene therapy could improve the rescue of the rd1
mice compared with previous attempts. We show that rescue of
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Figure 1 | Histological but no functional rescue in Pde6brd1/rd1-C3H mice. (a) Presence of bPDE and histological preservation (green) at 2 months post
injection following AAV9-mediated gene supplementation in Pde6brd1/rd1-C3H mice. Red arrows indicate the ONL in treated (i) and untreated areas (ii).
Scale bars, 250 (a) and 50mm (i, ii) (b) Absence of b-wave in the eyes of Pde6brd1/rd1-C3H mice treated with rAAV2/9.hRHO.hPDE6B. Representative ERG
traces from C57BL6 mouse and treated and untreated eye from Pde6brd1/rd1-C3H mice. Filled triangle indicates a-wave and open triangle denotes b-wave.
(c) Comparison of a-wave amplitudes between the eyes with AAV8- or AAV9-mediated expression of bPDE in Pde6brd1/rd1-C3H mice (n¼4 per group) and
C57BL6 (n¼5). Data represent mean±s.e.m. (d) Absence of bipolar response indicated by pharmacological blockage of the synaptic connection between
photoreceptors and bipolar cells in Pde6brd1/rd1-C3H mouse. Black traces represent recording before injection of L-AP4 and PDA. Red traces indicate
responses recorded from the same animal after intravitreal injection of L-AP4 and PDA that blocks the synaptic transmission between photoreceptor and
bipolar cells. Note that waveform remains relatively similar after the injection in the gene therapy-treated C3H mouse (lower traces), whereas a large
reduction of the positive peak (b-wave) is seen following the injection in C57BL6 mouse (upper traces).
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supplementation therapy is compromised by the presence of a
confounding mutation in the Gpr179 gene in most strains. After
removal of the Gpr179 mutation, PDE6B gene therapy results in
the effective rescue of structure and function of the Pde6b / 
retina for up to 1 year.
Results
AAV gene therapy restores photoreceptor function in rd1 mice.
An AAV2/9 vector carrying the human PDE6B gene
under the control of human rhodopsin promoter (rAAV2/
9.hRHO.hPDE6B) was injected subretinally at postnatal day
9 (P9) in female rd1 mice on the C3H/HeN background
(Pde6brd1/rd1-C3H). At 2 months of age (B7 weeks post
injection), histological evaluation of the treated eyes showed
substantial preservation of the outer nuclear layer (ONL) and
inner/outer segment structures that corresponded well with the
area immunopositive for bPDE (Fig. 1a). Conversely, outside the
area of bPDE immunepositivity the ONL was severely reduced to
a single layer, consistent with the known progress of retinal
degeneration in rd1 mice4. These results conﬁrmed that AAV9-
mediated PDE6B gene transfer results in the expression of bPDE
in rod outer segments and subsequent prevention of rod
photoreceptor death. We observed a similar result following the
administration of an AAV2/8 vector carrying the same construct
(Supplementary Fig. 1).
Electroretinography (ERG) performed at 7 weeks post injection
in the rAAV2/9.hRHO.hPDE6B-treated group, revealed that the
morphological preservation of the retina was accompanied by a
partial functional rescue of the a-wave, which represents rod
photoreceptor function. However, the b-wave, initiated by the
bipolar cells, was completely absent (Fig. 1b,c). Similar results
were also obtained when PDE6B gene was delivered using
AAV2/8 vector (Fig. 1c). The presence of an a-wave indicated the
successful restoration of bPDE activity and a functional
phototransduction cascade. Nonetheless, the lack of b-wave
indicated either a major defect in the synaptic transmission
between the photoreceptors and the immediate downstream
bipolar cells or an intrinsic dysfunction of the bipolar cells
themselves. This b-wave dysfunction is reminiscent of the
pharmacological blockade of photoreceptor-to-bipolar transmis-
sion, where the injection of a L-(þ)-2-amino-4-phosphonobu-
tyric acid (L-AP4) and cis-2,3-piperidine dicarboxylic acid (PDA)
cocktail into the eyes of wild-type (WT) C57/B6 mice abolishes
the b-, but not the a-wave24,25. Indeed, ERG traces before and
after pharmacological blockade showed essentially no change in
the waveform in the rAAV2/9.hRHO.hPDE6B-treated eyes of
Pde6brd1/rd1-C3H mice (Fig. 1d). These results indicate that,
despite the successful histological preservation of the retina
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Figure 2 | A Gpr179 mutation leads to bipolar dysfunction in the Pde6brd1/rd1-C3H line. (a) Three different ERG phenotypes observed in F2 backcross of
Pde6brd1/rd1-C3H and C57BL6. Note that in addition to mice with normal ERGs (left traces), those with no detectable responses (middle traces) and those
lacking b-wave in the presence of a-wave were observed. The ‘no b-wave’ ERGs were similar to the ERG waveform observed in Pde6brd1/rd1-C3H mice
treated with rAAV2/9.hRHO.hPDE6B. (b) Results of ERG phenotyping of 35 mice of F2 backcross. Wild-type ERG was by far the most frequent phenotype,
while the ‘no response’ and ‘no b-wave’ phenotype were similar in number. (c) Identiﬁcation of the homozygous mutations in the Gpr179 gene in the C3H
line. Ampliﬁed PCR fragments show the presence of the intronic insertion in the Gpr179 gene. The results were consistent with Pde6brd1/rd1-C3H mice
carrying homozygous Gpr179 mutations.
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were non-responsive following the restoration of photoreceptor
function.
Bipolar dysfunction in rd1 mice is caused by a Gpr179 mutation.
bPDE is a speciﬁc component of the phototransduction cascade,
which takes place exclusively at rod photoreceptor outer seg-
ments. Therefore, the absence of a bipolar cell response in the
treated Pde6brd1/rd1-C3H eyes with restored rod function was an
unexpected result. We reasoned that one of the most straight-
forward explanations would be the existence of an as yet
unknown genetic defect in the bipolar cells of the rd1-C3H/HeN
line. To test this hypothesis, we crossed Pde6brd1/rd1-C3H with
C57BL6 and then crossed the F1 animals. ERG recordings of
female F2 offspring, performed at 3 months of age, showed three
distinct ERG phenotypes: a normal ERG, as seen in wild-type
mice; a non-detectable ERG typical for rd1 mice and an ERG with
no b-wave that resembled the traces of the treated Pde6brd1/rd1-
C3H mice (Fig. 2a). The results of the phenotypic screening of
35 F2 animals were consistent with an autosomal recessive
Mendelian inheritance pattern for an absent b-wave; 17% of
animals had an absent b-wave; 25% had an absent ERG (pre-
sumably Pde6brd1/rd1genotype) and 57% had a normal ERG
(Fig. 2b).
At least four naturally occurring mice lines, that are, nob1,
nob2, nob3 and nob5, have been reported to harbour a similar ‘no
b-wave’ or ‘nob’ phenotype26–29. Through a literature search, we
noted that one of these lines (nob5), in which rod and cone ON-
bipolar cell function is absent, was originally derived from the
C3H line. As it was plausible that the Pde6brd1/rd1-C3H line could
carry the same mutation, a large intronic insertion in the Gpr179
gene, we investigated its presence in our mice. Indeed, PCR
analysis of Pde6brd1/rd1-C3H genome conﬁrmed the homozygous
intronic insertion in the Gpr179 gene to be present in the mice
with a ‘no b-wave’ phenotype (Fig. 2c). Furthermore, the
genotype of 27 F2 and 62 F3 animals was conﬁrmed by PCR
and showed the expected correlation with ERG recordings:
animals without an ERG were homozygous for the Pde6b
mutation, animals without a b-wave were homozygous for the
Gpr179 mutation and animals with normal ERGs had at least one
wild-type allele for both the genes. The Gpr179 mutation was also
identiﬁed in Pde6brd1/rd1-C3H mice from an alternative
independent supplier (Supplementary Fig. 2).
Functional rescue in rd1 mice without the Gpr179 mutation.
After establishing an F3 backcross of rd1 mice homozygous for
the Pde6b mutation, but devoid of the Gpr179 mutation
(Pde6brd1/rd1-F3), rAAV2/9.hRHO.hPDE6B was injected sub-
retinally in female P9 pups. At 13 weeks after the treatment,
fundus photography showed reduced pigment deposition, sug-
gesting a reduction in photoreceptor death, and larger retinal
vessels, possibly reﬂecting greater demands of nutrients in the
retina compared with the untreated contralateral eye (Fig. 3a).
The difference in vascular diameter was also readily recognizable
on retinal ﬂatmounts stained with the blood vessel marker iso-
lectin B4. The retinal vasculature in the treated eye was very well
preserved compared with the severe vascular attenuation in the
untreated eye (Fig. 3b). Optical coherence tomography (OCT)
imaging showed the presence of the ONL in the treated eyes, in
contrast with the untreated eyes that lacked a visible ONL
(Fig. 3c). The average thickness of the whole retina in treated eyes
was 154±30mm, which was equivalent to B70% (227±7mm) of
that observed in wild-type control mice devoid of both rd1 and
Gpr179 mutations (WT-F3 mice) established during the process
of the backcross (Fig. 3c). Histological sections from the
mid-central retina conﬁrmed the in vivo observation,
showing signiﬁcant preservation of the photoreceptors (Fig. 3d).
Quantitative analyses showed increased number of rows of
photoreceptor nuclei in treated eyes (mean±s.d.¼9±1 rows of
photoreceptors) compared with untreated eyes (1±0), corre-
sponding to 80% of wild-type controls (11±1). The number of
cone photoreceptors identiﬁed by peanut agglutinin (PNA)
staining was also increased in the treated eyes compared with
untreated, corresponding to 80% of wild-type controls (Fig. 3d).
The severe and rapid photoreceptor degeneration in rd1 mice
results in a complete absence of ERG responses, including cone-
mediated ones, at 1 month after birth4. At 3 weeks after the
treatment (B1 month after birth), we observed a substantial
retinal response in Pde6brd1/rd1-F3 mice. Both a- and b-waves
were clearly visible, conﬁrming the restoration of both
photoreceptor and bipolar cell function. The treated eyes, at the
brightest ﬂash intensity under scotopic conditions, had a-wave
and b-wave amplitudes that were 37% and 55%, respectively, of
the ERG amplitudes from isogenic control mice (WT-F3;
Fig. 4a,c). Meanwhile, the untreated eyes from Pde6brd1/rd1-F3
mice showed no detectable responses. Gene therapy restored
normal rod sensitivity, as determined by the dimmest light
intensity at which the retinal response emerged under scotopic
conditions (Fig. 4a,c). ERG recordings under photopic conditions
also demonstrated the preservation of cone photoreceptor
function. Treated animals, at the brightest ﬂash intensity, had
cone ERG a-wave and b-waves amplitudes that were 60% and
64%, respectively, of that of WT-F3 mice (Fig. 4b,d). Although
there was some reduction in ERG amplitudes, particularly
between the ﬁrst 3 weeks and the second month after injection,
they remained stable thereafter until at least 4 months after
treatment (Fig. 4e,f).
Restoration of visually-guided behaviours and visual acuity.T o
test whether restoration of retinal function by gene therapy
translates into improved vision, we used two different methods to
assess visually-guided behaviour. First, we analysed the behaviour
of female mice (freezing their motion) following fear-conditioned
learning, where the visual cues were paired with a mild foot shock
10 weeks after the injection of the vector. Treated Pde6brd1/rd1-F3
mice showed signiﬁcantly increased levels of freezing behaviour
upon presentation of the visual cue (baseline freezing, 28.5±5.2;
light-cued freezing, 68.4±6.2; mean±s.e.m.; Po0.01, Fig. 5a, red
bars) indicating that they had learned the association between the
light cue and the foot shock. The increase in freezing behaviour
was comparable to that measured in WT-F3 mice (baseline
freezing, 39.1±8.3; light-cued freezing, 81.6±6.3; mean±s.e.m;
Po0.05 Fig. 5a, black bars). In contrast, untreated Pde6brd1/rd1-
F3 did not demonstrate a signiﬁcant increase in freezing
behaviour during cue presentation (baseline freezing, 20.3±7.6;
light-cued freezing, 28.8±10.0; mean±s.e.m; Fig. 5a, blue bars).
To further investigate the quality of vision that was restored,
visual acuity was measured by tracking head movements in
response to horizontally moving sinusoidal grating using
Optomotry 6 weeks after injection of vector under the brightest
test condition possible (62cdm 2). The untreated Pde6brd1/rd1-
F3 mice had signiﬁcantly worse visual acuity (0.08±0.02 cycles
per degree; mean±s.e.m.) compared with the age-matched
WT-F3 mice (0.41±0.04 cycles per degree; mean±s.e.m.).
Following treatment, an improvement was observed for the treated
right eye (counter-clockwise (CCW) direction; 0.41±0.03 cycles
per degree; mean±s.e.m.) but not for the untreated eye (clockwise
direction; 0.02±0.00 cycles per degree; mean±s.e.m.), indicating
near-normal visual acuity in the treated eye, whereas the acuity of
the untreated eye remained at background levels (Fig. 5b).
ARTICLE NATURE COMMUNICATIONS | DOI: 10.1038/ncomms7006
4 NATURE COMMUNICATIONS|6:6006|DOI: 10.1038/ncomms7006|www.nature.com/naturecommunications
& 2015 Macmillan Publishers Limited. All rights reserved.WT-F3 untreated
WT-F3 untreated
15
Rhodopsin
PNA
*** ***
10
A
v
e
r
a
g
e
 
n
u
m
b
e
r
 
o
f
 
P
R
 
r
o
w
s
5
0
WT-F3 untreated
300 ***
***
***
200
100
WT - F3
Pde6b  rd1/rd1  untreated - F3
Pde6b  rd1/rd1  treated - F3
*** ***
30
40
A
v
e
r
a
g
e
 
n
u
m
b
e
r
 
o
f
 
P
N
A
 
+
 
c
e
l
l
s
10
20
0
R
e
t
i
n
a
l
 
t
h
i
c
k
n
e
s
s
/
 
μ
m
 
(
O
C
T
)
0
WT - F3
GCL
INL
ONL
RPE
Pde6brd1/rd-F3 untreated
Pde6brd1/rd-F3 untreated
Pde6brd1/rd-F3 untreated
Pde6b rd1/rd1 untreated - F3
Pde6b rd1/rd1 treated - F3
Pde6brd1/rd1-F3 treated
Pde6brd1/rd-F3 treated
Pde6brd1/rd1-F3 treated
*
*
*
WT - F3 Pde6brd1/rd1
untreated - F3
Pde6brd1/rd1
treated - F3
WT - F3 Pde6brd1/rd1
untreated - F3
Pde6brd1/rd1
treated - F3
Figure 3 | Preservation of structure after AAV-mediated gene therapy in Pde6brd1/rd1-F3 mice. (a) Fundus photos from a treated and an untreated eye
of Pde6brd1/rd1-F3 mouse and a normal eye of a WT-F3 control. Note that retinal vessels (arrowheads) are clearly visible in the treated (bottom) Pde6brd1/rd1-
F3 mouse and WT-F3 mouse (top), whereas vessels in the untreated eye are not very visible (middle). Instead, areas of pigmentation (asterisks) are visible
in the untreated eye of Pde6brd1/rd1-F3 mouse. (b) Retinal ﬂatmount stained with isolectin B4. Note retinal vessels (arrowhead) are severely attenuated in
the untreated Pde6brd1/rd1-F3 retina (middle panel) compared with the treated (right panel) or the WT-F3 control retina (left panel).Scale bar,250mm.
(c) OCT images from a treated and an untreated eye of Pde6brd1/rd1-F3 and normal eye of a WT-F3 control. Quantiﬁcation of retinal thickness: individual
measurements obtained from six animals (n¼5 for WTcontrol) are shown. ***Po0.0001 One-way analysis of variance (ANOVA) with Tukey’s multiple
comparison test. Data represent mean±s.e.m. (d) Histological retinal sections from the mid-central retina of a treated and an untreated eye of Pde6brd1/rd1-
F3 and a normal eye of a WT-F3 control. Quantiﬁcation of number of DAPI labelled photoreceptor (PR) rows (left) and number of cones per section
(PNAþ cells—right). ***Po0.0001 One-way ANOVA with Tukey’s multiple comparison test, n¼5 for control, n¼6 for treated and untreated animals.
Data represent mean±s.e.m. Scale bar, 50mm.
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Examination of eyes, 13 months after treatment with rAAV2/
9.hRHO.hPDE6B, showed the presence of a substantial photo-
receptor layer with visible inner and outer segment structures
while no discernable photoreceptors were visible in the untreated
eyes (Supplementary Fig. 3). Immunohistochemical assessment
conﬁrmed that the treated photoreceptors expressed rhodopsin
and the bPDE in the outer segments. This was accompanied by
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Figure 4 | Restoration of photoreceptor and bipolar cell function in Pde6brd1/rd1-F3 mice. (a–d) Scotopic and photoptic ERGs at 3 weeks following gene
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scotopic a-wave and b-wave components (Supplementary
Fig. 4A,B). Although visual acuity was reduced at 11 months
compared with the early time points, it was still substantial and
signiﬁcantly higher than in untreated eyes (Supplementary Fig. 4C).
Discussion
This study demonstrates, for the ﬁrst time, the unambiguous
structural and functional rescue of rod photoreceptors in rd1
mice, the most widely studied model of retinal degeneration. We
have shown that simple gene transfer of the defective gene, Pde6b,
into the commonly used laboratory rd1 strain (C3H/HeN) can
rescue rod photoreceptor function, but fails to restore the
downstream signalling. We discovered that this is explained by
the presence of an additional naturally occurring mutation in the
Gpr179 gene within the same line that abolished the function of
retinal ON-bipolar cells, including rod bipolar cells. Indeed, the
restoration of both photoreceptor and bipolar function was only
possible after crossing this mutation out from the C3H/HeN
mouse line.
C3H mice lines with the rd1 mutation are widely distributed
for research purpose by most major animal suppliers worldwide.
Indeed, a review of over 130 research articles, where the rd1
background was stated, shows that 67% of these studies use the
C3H line. Our investigations suggest that the Gpr179 mutation
may be present in many C3H lines, including those provided by
the Jackson Laboratory, Charles River and Harlan Laboratories.
The spontaneous mutation in the Gpr179 gene was ﬁrst identiﬁed
as the cause of nob5 mice, a strain that originated from the C3H
line bred by the Jackson Laboratory29. We have directly
conﬁrmed by PCR the presence of the homozygous Gpr179
mutation in the C3H/HeN line distributed by both Charles River
and Harlan Laboratories. Historically, the Jackson Laboratory
received C3H mice from Heston in 1948 (C3H/HeJ strain) while
Charles River received C3H mice from the National Institute of
Health (NIH, USA) in 1974, which were originally provided to
the NIH by Heston in 1951 (C3H/HeN strain)30. Thus, the
Gpr179 mutation was likely already present at the time the line
was propagated to the Jackson Laboratory by Heston in 1948.
This would indicate that most, if not all, of the studies using
rd1-C3H mice as a model of retinal degeneration published
within the past 65 years (since 1948) probably used the double
mutants unknowingly and that the conclusions, based on the
erroneous assumption that these mice are a simple model of
photoreceptor degeneration, should be interpreted with caution.
In particular, since Gpr179 expression is speciﬁc to ON-bipolar
cells29, any rescue of vision in this mouse line must be limited to
the OFF cone bipolar pathway. This also raises the question of
how approaches such as transplantation of rod precursors in
C3H/HeN mice can lead to the efﬁcient rescue of vision as
recently reported by Singh et al.31. Considering the lack of
function in the canonical ON rod bipolar pathway, the extensive
contacts observed between the transplanted rods and rod bipolar
cells cannot explain the reported rescue of vision. This would
require a more complex explanation, such as the extensive wiring
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Figure 5 | Supplementation of PDE6B gene to rods restores retinotopy and visual function. (a) Visually cued fear conditioning paradigm. On the day of
training, each mouse was placed in a conditioning chamber and received six presentations of a 5-s ﬂickering light stimulus paired with a co-terminating 2-s
foot shock (left panel). Recall of light-cued memory was tested 24h post training by measuring the baseline and light-cued freezing levels in a novel
environment (left panel, see methods). Rescue of visually cued behaviour in PDE6B treated mice (right panel). Bar graph represents mean average of the
percentage of time spent freezing during a baseline period without light stimulation (outlined bars) and during presentation of the light cue (ﬁlled bars).
Light-cued memory was assessed for three different experiment groups; Pde6brd1/rd1-F3 treated (red bars, n¼6), Pde6brd1/rd1-F3 untreated (blue bars,
n¼5) and untreated wild-type-F3 (black bars, n¼4). The experiment was conducted at 10 weeks after treatment. (b) Restoration of normal visual acuity in
the treated eyes of Pde6brd1/rd1-F3 mice. Note that when visual acuity in response to CCW direction representing the function of the treated eyes and to
clockwise direction probing that of the untreated eyes separately within the same Pde6brd1/rd1-F3 animal (n¼6), treated eyes showed comparable acuity to
those of the WT-F3 controls (n¼5), whereas untreated eyes showed similar values to the untreated Pde6brd1/rd1-F3 mice (n¼5). The experiment was
conducted at 6 weeks after treatment. Data represent mean±s.e.m. Statistical signiﬁcance was assessed with a one-way analysis of variance, * denotes
P valueo0.05. Data represent mean±s.e.m.
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not been reported.
We cannot fully exclude that a mutation in another gene,
closely linked to the Gpr179 gene, may be responsible for the
observed phenotype. However, in view of the similarity with the
disease phenotype of GPR179-deﬁcient patients, mice and
zebraﬁsh29, we consider this unlikely. The exact impact of the
large intronic insertion in Gpr179 is unknown. Since a targeted
sequencing of the entire Gpr179 gene identiﬁed no other
mutations29, it is likely that the large intronic mutation affects
the production of the encoded protein. As it does not directly
affect the coding exons and because its mRNA was virtually
absent in the retina29, it is likely that the mutation results in the
aberrant splicing of the gene followed by a nonsense-mediated
decay of the mRNA. Irrespective of the actual mechanism, our
ﬁndings show that when using rd1 mice on the C3H background
as a model of photoreceptor degeneration it is essential to ensure
that the mice are free of the Gpr179 mutation. The results
presented here, together with the recent identiﬁcation of the rd8
mutation in many transgenic mouse lines32,33, highlight the risks
of using inbred mouse strains that potentially carry mutations in
more than one gene. Although our work does not necessarily
invalidate the results of previous studies using rd1 mice, the
increasing emphasis on functional outcomes and vision means
that future studies using this animal model might be severely
compromised if the Gpr179 status of the animals is not taken into
account.
In addition to the robust structural rescue and restoration of
the retinal circuit, treated mice also showed vision-guided
behaviour that was absent in untreated animals. The most
intriguing outcome was the demonstration of normal visual
acuity in the treated eye that contrasted sharply with the
completely blind contralateral untreated eye. This is a level of
therapeutic beneﬁt that has not been demonstrated by previously
reported gene supplementation therapies6–8,13,14. Of these
previous attempts, the PDE6B cDNA iontophoresis study by
Souied et al.8 achieved the best results. They appear to use the rd1
mice on a C57BL/6 background and achieved a morphological
rescue of about 45% of wild-type ONL thickness; it was also the
only study to report a small ERG recovery of about 10% of wild-
type levels. In this study, however, we were able to achieve an 80%
rescue of ONL thickness and an ERG recovery of around 60%
compared with the wild-type controls. The improved rescue
reported here could be explained by several factors including the
use of more efﬁcient gene delivery tools, the use of a strong rod-
speciﬁc promoter and the age at which the animals were treated.
Both AAV8 and AAV9 have been shown to be very efﬁcient in
targeting photoreceptors and are capable of delivering high levels
of transgene expression. In this study, we established that the two
vectors are capable of delivering similar levels of functional and
morphological rescue (data not shown). While the treated eyes in
this study showed some decline in retinal function during the
year following injection, none of the previous studies were able to
demonstrate substantial morphological rescue beyond 6 weeks
post treatment. This study demonstrates, for the ﬁrst time, a
robust, long-term structural, functional and behavioural rescue of
blind rd1 mice and supports the development of gene therapy for
retinitis pigmentosa caused by mutations in PDE6B.
Methods
Animals. The rd1 mice (C3H/HeN) and wild-type mice (C57BL/6J) were
purchased from Harlan Laboratories (Blackthorn, UK). Additional rd1 mice were
purchased from Charles River (Margate, UK). All mice were maintained under
cyclic light (12h light–dark) conditions; cage illumination was 7 foot-candles
during the light cycle. All experiments were approved by the local Institutional
Animal Care and Use Committees (UCL, London, UK) and conformed to the
guidelines on the care and use of animals adopted by the Society for Neuroscience
and the Association for Research in Vision and Ophthalmology (Rockville, MD,
USA). Animal group sizes were based on power calculations (power¼0.9,
a¼0.05).
Backcrossing and genotyping. Several homozygous rd1 female mice were paired
with C57BL/6J wild-type male mice. The heterozygous litters from this crossing
(F1) were then paired with each other. The resulting litters (F2) from the F1
heterozygous pairing were phenotyped by ERG, PCR and DNA sequencing. Ear
clips were collected from all F2 litters and the genomic DNA (gDNA) was extracted
using the DNAreleasy (Anachem, Luton, UK) following the manufacturer’s
protocol. Extracted gDNA was used for PCR ampliﬁcation of Gpr179 and Pde6b
gene fragments using GoTaq Green (Promega, UK) as follows: 12.5ml of GoTaq
Green Master Mix, 1ml of each primer at 10mM, 2ml of gDNA and water up to a
total of 25ml. Primers used are shown in Supplementary Table 1 and cycling
conditions in Supplementary Table 2. For the Gpr179 genotyping separate
reactions were set up for the wild-type and for the mutant allele screening using
different reverse primers but the same forward primer (GPR179 F1). Since the rd1
allele has a point mutation, the genotype was determined by sequencing the PCR
product. The sequence for the GPR179 R3, which binds to the mutant allele only,
was deﬁned after using the GPR179 F1 primer to sequence intron 1 and deﬁne the
exact position and partial sequence of the large insertion that is responsible for the
non-functional Gpr179 gene in these animals.
Plasmid constructs, viral production and injection procedure. The transgene
construct (pD10/hRho-hPDE6B) was kindly provided by Professor Alberto
Auricchio (TIGEM Institute, Naples, Italy) and contains the human cDNA
sequence of the PDE6B gene downstream of the short human rhodopsin promoter
described previously33. The plasmids were packaged into AAV8 and AAV9 to
generate two recombinant AAV viral vectors, AAV8.hRho.hPDE6B and
AAV9.hRho.hPDE6B, as described below (ref. 34). Recombinant AAV8 vector and
AAV9 vector were produced through a triple transient transfection method. The
plasmid construct (pD10), AAV serotype-speciﬁc packaging plasmid and helper
plasmid, in a ratio of 1:1:3 at 20mg total DNA per ml of DMEM, were mixed with
Polyethylenimine (Polysciences Inc.) to a ﬁnal concentration of 50mgml 1 and
incubated for 100 at room temperature to form transfection complexes that were
added to 293 T cells at 50mg DNA per 15-cm plate and left for 72h. The cells were
collected, concentrated and lysed by freeze–thaw (3x) in PBS to release the vector.
AAV8 was bound to an AVB Sepharose column (GE Healthcare), and eluted with
50mM Glycine pH2.7 into 1M Tris pH 8.8. AAV9 was puriﬁed by size separation
on a Sephacryl S300 column, followed by anion exchange chromatography using a
POROS 50 HQ column, eluting the vector in 20mM bis-tris propane, 20mM
Trizma Base and 0.24M NaCl pH9. Vectors were washed in 1  PBS and
concentrated to a volume of 100–150ml using Vivaspin 4 (10kDa) concentrators.
Viral particle titres were determined by comparative dot-blot DNA prepared from
puriﬁed viral stocks and deﬁned plasmid controls. Puriﬁed vector titres used for all
experiments were 2 1012 viral particles per ml 1. Subretinal injections were
performed under direct retinoscopy thorough an operating microscope. The tip of
a 1.5-cm, 34-gauge hypodermic needle (Hamilton) was inserted tangentially
through the sclera of the mouse eye, causing a self-sealing wound tunnel. The
needle tip was brought into focus between the retina and retinal pigment. Animals
received double injections of 1.5ml each to produce bullous retinal detachments in
the superior and inferior hemisphere around the injection sites. Eyes were assigned
as treated and (contralateral) control eyes using a randomization software.
Electroretinogram (ERG). ERGs were recorded from both eyes from mice with
and without Pde6brd1/rd1 mutation. All animals were dark adapted overnight before
ERG recordings. After dilating the pupils using 2.5% phenylephrine and 1.0%
tropicamide, ERGs were recorded using commercially available equipment (Espion
E2, Diagnosys, LLC, MA). Scotopic recordings were obtained from dark-adapted
animals at the following increasing light intensities: 0.0001, 0.001, 0.01, 0.1, 1, 10,
31.2 and 75.2cds 1m 2 for 8-step protocol and additional 2 ﬂash intensities
(0.000001 and 0.00001) for 10-step protocol. Photopic recordings were performed
following 5min light adaptation intervals on a background light intensity of
30cdm 2, which was also used as the background light for the duration of
photopic recordings. Photopic light intensities used were 0.01, 0.1, 1, 10, 31.2 and
72.5 20cds 1m 2. In a small subset of wild-type and C3H/HeN mice, ERGs were
recorded after 2ml of PBS with 20mM L-AP4 (l-2-amino-4-phosphobutyric acid;
Abcam) and 100mM 2,3 cis-PDA(Abcam) were injected intravitreally into the eye,
which has been previously shown to stably abolish the functional connection
between photoreceptors and bipolar cells for at least 24h (ref. 35).
Fundus photography and optical coherence tomography (OCT). Fundus photos
were obtained using topical endoscopic fundus imaging as previously described36.
A 5-cm endoscope 3mm in outer diameter (1218 AA; Karl Storz, Tuttlingen,
Germany), was connected by ﬁbre-optic cable to a Nikon D300s digital camera
with a 12.3 megapixel charge-coupled device sensor and Viscotears (Novartis
Pharmaceuticals, UK) was used as a coupling agent for corneal contact. OCT
images were obtained using the Spectralis HRAþOCT (Heidelberg engineering,
Heidelberg, Germany) using the 30 angle lens to determine the thickness of the
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obtained at standardized position (about 2–3 disc diameters away from the optic
disc) in the superior, inferior (both horizontal scans), nasal and temporal (both
vertical scans) retina. The OCT images were exported and processed in Adobe
Photoshop CS 2 (Adobe Systems Incorporated, San Jose, USA). The processed
b-scans were imported into the Fiji image processing software37 and scaled by the
vertical scale bar. Five thickness measures at equidistant positions across each
b-scan were obtained resulting in a total of 20 individual measures per eye.
Statistical analyses were performed using GraphPad Prism 5 for Windows
(GraphPad Software Inc, La Jolla, USA).
Immunohistochemistry. Animals were killed, the eyeballs enucleated and cornea,
lens and iris removed. For retinal sections, the eyecups were ﬁxed in 4% paraf-
ormaldehyde for 1h and incubated in 20% sucrose for 1h, all at room temperature,
before embedding in optimal cutting temperature medium. 18-mm cryosections
were cut in sagittal orientation, rinsed with PBS and blocked in 10% normal goat
serum, 3% bovine serum albumin and 0.1% Triton-X100. Retinal ﬂatmounts were
dissected during the 1-h ﬁxation period in 4% paraformaldehyde and blocked with
5% normal goat serum, 1% bovine serum albumin and 3% Triton-X100. The
respective samples were incubated with primary antibodies in block solution
at 4C overnight using rabbit anti-PDE6b (diluted 1:500; PA1-722,Thermo
Scientiﬁc), mouse anti-rhodopsin (diluted 1:1,000; Clone RET-P1, O4886, Sigma
Aldrich), lectin PNA Alexa488 conjugate (diluted 1:200; L21409, Life Technologies)
and biotin conjugated Isolectin B4 (BSI-B4, L2140, Sigma). Following PBS washes,
the respective combination of secondary antibodies (all diluted 1:500, Life
Technologies) including goat anti-rabbit Alexa Fluor 546 (A11035), goat anti-
mouse Alexa Fluor 633 (A21052) and streptavidin, Alexa Fluor 633 conjugate
(S21375) were used to label the samples before these were counterstained with
40,6-diamidino-2-phenylindole (DAPI) and mounted with DAKO ﬂuorescent
mounting media (DAKO, S3023, Denmark). Images were acquired by confocal
microscopy (Leica DM5500Q). For ONL thickness quantiﬁcation the number of
rows of DAPI-positive nuclei in the ONL were counted on single-layer confocal
images taken from the superior and inferior mid-central retina of each eye and
averaged per animal. For quantiﬁcation of cone outer segment the presence of
PNA-positive cells were counted on corresponding standardized sized projection
images. The average per animal is derived from all the values obtained from three
sections per eye with two images each, one from the inferior and one from the
superior retina. One-way analysis of variance ( Mean±s.d.) followed by Bonferri
post-test was performed to determine the signiﬁcance.
Fear conditioning. Mice were trained and tested using a commercially available
fear conditioning system (Med Associates). To ensure blind conditions, the
experimenter performing the training and testing was always blind to the strain of
mouse and treatment conditions. In brief, the setup consisted of a conditioning
chamber (20 30cm) with a stainless steel grid ﬂoor placed inside a sound-
attenuating cubicle. Mouse behaviour was monitored constantly during training
and testing by means of a built-in infrared digital video camera (30 frames per s 1
acquisition rate) and infrared illumination. VideoFreeze software (Med Associates)
was used to control the delivery of the LED light stimulus (4.49 log cds 1m 2)
with a diffuser in front and shock. The light stimulus consisted of a single LED
(535nm, Thorlabs) 5-Hz 50-ms ﬂicker generated via an arduino interface (Arduino
Software) positioned on a side panel of the conditioning chamber. To ensure that
the context in which training and testing took place were different, ﬂoor and
curved wall panels were inserted into the chamber for the testing session.
Mice were placed inside the chamber and underwent one conditioning session,
consisting of six pairings of a 5-s light stimulus that co-terminated with a 2-s
0.65mA foot shock. Inter-trial interval was pseudo-randomized (average interval
90s). Following the training session mice were returned to the home cage. Twenty-
four hours after training, mice were tested for visually cued memory recall. Mice
were placed in the test chamber and monitored for a total of 360s. The
conditioning light stimulus was presented continuously for the last 120s of the test
session. All data was acquired and scored automatically by VideoFreeze software
(Med Associates). In brief, the software is calibrated before placing the animal in
the chamber. The software then measures the pixel changes that take place between
every video frame. The motion threshold was set to be as low as possible (20
motion index units), and the continuous freezing count was set to the frame rate to
ensure the most sensitive read-out of motion. To assess light-cued memory recall
the percentage time of freezing behaviour was averaged for the 2min immediately
before and following the light stimulus onset. Statistical signiﬁcance was assessed
with a one-way analysis of variance. Results are presented as mean±s.e.m.
Optomotry. Visual acuities were measured by observing the optomotor responses
of mice to rotating sinusoidal gratings (OptoMotry, Cerebral Mechanics)38. The
protocol used yields independent measures of the acuities of right and left eyes
based on the unequal sensitivities of the two eyes to pattern rotation as only motion
in the temporal-to-nasal direction evokes the tracking response. As a result, the
right and the left eyes are most sensitive to CCW and clockwise rotations,
respectively39. A double-blind two-alternative forced choice procedure was
employed, in which the observer was ‘blind’ to the direction of pattern rotation,
to whether it was a treated or untreated rd1 mouse or age-matched wild-type
control animal (C57BL6). The mice were housed in a standard lighting condition
for at least 6h before they were placed in the recording chamber. The observer
selected the direction of pattern rotation based on the animal’s optomotor response
and the monitors returned to 50% grey until the next trial. Acuity was deﬁned as
the highest spatial frequency (at 100% contrast) yielding a threshold response. The
measurement was performed using the brightest light condition possible
(62cdm 2). Visual acuity was measured in both the eyes of the tested animal and
averaged or separately analysed for each eye after four trials were conducted on
four separate days. The measurement was carried out on rd1 mice 11 weeks after
treatment together with age-matched isogenic controls. Statistical signiﬁcance was
assessed with a Student’s t-test. Results are presented as mean±s.e.m.
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